VerifyMe (VRME) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	LLTI
Entity Registrant Name	LASERLOCK TECHNOLOGIES INC
Entity Central Index Key	1104038
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		307,578,149

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$74,572	$63,956
Inventory	109,360	97,360
Prepaid expenses	178,454	181,086
TOTAL CURRENT ASSETS	362,386	342,402
PROPERTY AND EQUIPMENT
Capital equipment, net of accumulated depreciation of $178,518 and $161,205 as of March 31, 2015 and December 31, 2014	57,508	74,821
OTHER ASSETS
Deposits	37,197	37,197
Patents and Trademark, net of accumulated amortization of $122,615 and $118,502 as of March 31, 2015 and December 31, 2014	103,473	107,586
TOTAL OTHER ASSETS	140,670	144,783
TOTAL ASSETS	560,564	562,006
CURRENT LIABILITIES
Accounts payable and accrued expenses	5,544,281	5,217,770
Accrued interest-related parties	175,794	43,215
Deferred revenue	10,417	16,667
Senior secured convertible notes payable-related parties	114,000	114,000
Notes payable	959,102	812,553
TOTAL CURRENT LIABILITIES	6,803,594	6,204,205
LONG-TERM LIABILITIES
Warrant liability	6,201,233	6,370,709
Accrued interest-related parties		112,885
TOTAL LONG-TERM LIABILITIES	6,201,233	6,483,594
TOTAL LIABILITIES	13,004,827	12,687,799
CONTINGENCIES
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, $ .001 par value; 75,000,000 shares authorized; 21,111,111 shares issued and outstanding as of March 31, 2015 and December 31, 2014	633,333	633,333
Common stock, $ .001 par value; 675,000,000 shares authorized; 337,374,052 shares issued and 307,578,149 outstanding at March 31, 2015 and December 31, 2014	337,374	337,374
Additional paid in capital	24,658,460	24,713,294
Treasury stock, at cost (29,795,903 shares at March 31, 2015 and December 31, 2014	-113,389	-113,389
Accumulated deficit	-37,960,041	-37,696,405
STOCKHOLDERS' DEFICIT	-12,444,263	-12,125,793
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$560,564	$562,006

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accumulated depreciation on capital equipment	$178,518	$161,205
Accumulated amortization, patent and trademarks	$122,615	$118,502
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	75,000,000	75,000,000
Preferred stock, shares issued	21,111,111	21,111,111
Preferred stock, shares outstanding	21,111,111	21,111,111
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	337,374,052	337,374,052
Common stock, shares outstanding	307,578,149	307,578,149
Treasury stock, shares	29,795,903	29,795,903

Statements_of_Operations_Unaud

Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
NET REVENUES
Sales	$0		$0
Royalties	6,250
TOTAL NET REVENUE	6,250
COST OF SALES	0		0
GROSS PROFIT	6,250
OPERATING EXPENSES
General and administrative	83,901		244,496
Legal and accounting	11,113		113,326
Payroll expenses	170,904	[1]	954,328	[1]
Research and development	120,386		864,729
Sales and marketing	22,808		51,922
Total operating expenses	409,112		2,228,801
LOSS BEFORE OTHER INCOME	-402,862		-2,228,801
OTHER INCOME (EXPENSE)
Interest expense	-30,250		-10,907
Change in fair value of warrants	169,476		-890,000
Change in fair value of embedded derivative liability			-300,000
TOTAL OTHER INCOME (EXPENSE)	139,226		-1,200,907
NET LOSS	($263,636)		($3,429,708)
BASIC (in dollars per share)	$0		($0.01)
DILUTED (in dollars per share)	$0		($0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC (in shares)	307,578,149		297,571,958
DILUTED (in shares)	307,578,149		297,571,958
[1]	- includes share based compensation of $(54,834) and $740,954 for the three months ended March 31, 2015 and 2014

Statements_of_Operations_Unaud1

Statements of Operations (Unaudited) (Parenthetical) (Payroll expenses, USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Payroll expenses
Share based compensation	($54,834)	$740,954

Statements_of_Changes_in_Stock

Statements of Changes in Stockholders' Deficit (USD $)	Total	Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit
Balance at Dec. 31, 2014	($12,125,793)	$633,333	$337,374	$24,713,294	($113,389)	($37,696,405)
Balance (in shares) at Dec. 31, 2014		21,111,111	307,578,149
Fair value of employee stock options	-54,834			-54,834
Net loss	-263,636					-263,636
Balance at Mar. 31, 2015	($12,444,263)	$633,333	$337,374	$24,658,460	($113,389)	($37,960,041)
Balance (in shares) at Mar. 31, 2015		21,111,111	307,578,149

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($263,636)	($3,429,708)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of options issued in exchange for services	-54,834	740,954
Accretion of discount on notes payable	10,447
Change in fair value of warrant liability	-169,476	890,000
Change in fair value of embedded derivative liability		300,000
Amortization and depreciation	21,426	20,590
Stock and warrants issued in exchange for technology		844,000
(Increase) decrease in assets
Inventory	-12,000
Prepaid expenses	2,632	2,632
Increase (decrease) in liabilities
Accounts payable and accrued expenses	346,205	-75,100
Deferred revenue	-6,250
Net cash used in operating activities	-125,486	-706,632
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable	136,102
Net cash provided by financing activities	136,102
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	10,616	-706,632
CASH AND CASH EQUIVALENTS-BEGINNING OF PERIOD	63,956	1,285,973
CASH AND CASH EQUIVALENTS-END OF PERIOD	74,572	579,341
Cash paid during the year for:
Interest	0	0
Income taxes	0	0
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Cashless exercise of options		$2,714

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of the Business
	LaserLock Technologies Inc. (the “Company” or “LaserLock”) was incorporated in the State of Nevada on November 10, 1999. The Company is based in Washington, D.C. and its common stock is quoted on the OTC Pink under the ticker symbol “LLTI”. A high-tech solutions company in the field of authenticating people and products, LaserLock offers state-of-the-art solutions to combat identity fraud and counterfeiting utilizing multi-factor authentication and a suite of security pigments for governments, health care providers, the gaming industry, the financial services industry and high-end retailers.
	The Company invests in developing new proprietary color shifting inks that it believes will allow it to penetrate broader markets and result in increased revenues. The Company refines its technologies and their applications, and now has what it believes to be one of the most cost effective and efficient authentication technologies available. Its most recent technology takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in numerous potential new applications ranging from credit cards to drivers licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologies can also be used to protect DVDs, apparel, pharmaceuticals, and virtually any other physical product.
	The Company’s digital solution is a multi-platform (iOS and Android) strong authentication solution that integrates biometrics and geo-location tagging. The solution completely eliminates passwords and the inherently weak security they provide. The solution also removes the user complexity associated with having to manage many complex passwords. The solution can be delivered either as a high availability cloud service, managed by the Company, or as licensed software product for operation on the client’s premises.
	The solution integrates three independent authentication factors – something you have (for instance a smartphone), something you know (for instance a color gesture swipe) and something you are (for instance your facial geometry)—into a simple, fast, intuitive solution. The system can also accurately determine the precise location of the individual using a variety of mechanisms including GPS, cell tower triangulation, IP or Wi-Fi address. Because the solution incorporates biometrics it completely eliminates the possibility that users might share their authentication credentials. The combination of biometrics and geolocation provides extremely strong transactional evidence, making it nearly impossible for an end-user to refute having been part of a transaction.
	The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalize the Company’s current technology.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on form 10-K for the year ended December 31, 2014, as filed with the SEC. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Comprehensive Income
	The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash, accounts payable and accrued expenses and notes payable. The carrying value of cash, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable and convertible debt approximates its fair value based on rates and other terms currently available to the Company for similar debt instruments.
	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
	Concentration of Credit Risk Involving Cash and Cash Equivalents
	The Company’s cash and cash equivalents are held at two financial institutions. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
	Inventory
	Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
	Property and Equipment
	Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations.
	Patents and Trademark
	The Company has filed eleven patent applications relating to the company technology. Currently we have 7 U.S. patents, 4 U.S. applications pending for allowance, and 5 foreign applications pending for allowance. The Company has also purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be17 to 20 years.
	Long-Lived Assets
	The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
	Deferred Financing Costs
	Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50 “Debt – Modification and Extinguishments.”
	Convertible Notes Payable
	Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method which approximates the effective interest method.
	Derivative Instruments
	The Company evaluates its convertible debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative, if required to be bifurcated, is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
	Revenue Recognition
	In accordance with SEC Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
	Income Taxes
	The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
	All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid-in capital in stockholders’ equity over the applicable service periods.
	Advertising Costs
	Advertising costs are expensed as incurred. Advertising costs were approximately $158 and $27,283 for the three months ended March 31, 2015 and 2014 and are included in sales and marketing expenses.
	Research and Development Costs
	In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $120,386 and $864,729.
	Basic and Diluted Net Income per Share of Common Stock
	The Company follows FASB ASC 260 when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Since the Company reported a net loss for the three months ended March 31, 2015 and 2014, common stock equivalents, including convertible preferred stock, convertible debt, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share during the years were the same.
	Segment Information
	The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by ASC 280 can be found in the financial statements.
	Recently Adopted Accounting Pronouncements
	As of March 31, 2015 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements.
	Recently Issued Accounting Pronouncements Not Yet Adopted
	As of March 31, 2015, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company’s financial statements through 2016.
	Reclassifications
	Certain amounts in 2014 statement of operations have been reclassified in order for them to conform with the 2015 presentation.

Management_Plans

Management Plans	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Management Plans	NOTE 2 – MANAGEMENT PLANS
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses and experienced negative cash flow from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company does not believe that its existing cash resources will be sufficient to sustain operations during the next twelve months. The Company currently needs to generate revenue in order to sustain its operations. In the event that the Company cannot generate sufficient revenue to sustain its operations, the Company will need to reduce expenses or obtain financing through the sale of debt and/or equity securities. The issuance of additional equity would result in dilution to existing stockholders. If the Company is unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to the Company, the Company may be unable to execute upon the business plan or pay costs and expenses as they are incurred, which could have a material, adverse effect on the business, financial condition and results of operations.
	If sufficient revenues are not generated to sustain operations or additional funding cannot be obtained in the short term, the Company will need to reduce monthly expenditures to a level that will enable the Company to continue until such funds can be obtained.
	Successful completion of the Company’s development program, and the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investment or achieve an adequate sales level.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 3 – PROPERTY AND EQUIPMENT
	Equipment consists of the following:
		March 31,		December 31,
		2015		2014
	Furniture and Fixtures	$	219,871	$	219,871
	Equipment		16,155		16,155
			236,026		236,026
	Less: Accumulated depreciation		178,518		161,205
		$	57,508	$	74,821
	Depreciation of property and equipment was $17,313 and $17,313, respectively, for the three months ended March 31, 2015 and 2014.

Patents_and_Trademark

Patents and Trademark	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and Trademark	NOTE 4 – PATENTS AND TRADEMARK
	The Company has seven issued patents and filed for four additional provisional patents for anti-counterfeiting technology. Accordingly, costs associated with the registration of these patents and legal defense have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents (17 to 20 years). During three months ended March 31, 2015 and 2014, the Company capitalized $0 and $21,954 of patent costs. Amortization expense for patents was $4,114 and $3,277 for the three months ended March 31, 2015 and 2014.
	On March 30, 2015, the Company was advised by the United States Patent and Trademark Office (“USPTO”) that its petition for an unintentional delayed payment for an unpaid maintenance fee to reinstate its patent was granted by the USPTO. The patent, for a counterfeiting ink detection system, was granted on November 2, 2004.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 5 – INCOME TAXES
	Income tax expense was $0 for the three months ended March 31, 2015 and 2014.
	As of January 1, 2015, the Company had no unrecognized tax benefits, and accordingly, the Company did not recognize interest or penalties during 2014 related to unrecognized tax benefits. There has been no change in unrecognized tax benefits during the three months ended March 31, 2015, and there was no accrual for uncertain tax positions as of March 31, 2015. Tax years from 2011 through 2014 remain subject to examination by major tax jurisdictions.
	There is no income tax benefit for the losses for the three months ended March 31, 2015 and 2014, since management has determined that the realization of the net tax deferred asset is not assured and has created a valuation allowance for the entire amount of such benefits.

Senior_Secured_Convertible_Not

Senior Secured Convertible Notes Payable -Related Parties	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Senior Secured Convertible Notes Payable -Related Parties	NOTE 6 – SENIOR SECURED CONVERTIBLE NOTES PAYABLE –RELATED PARTIES
	In February 2006, the Company commenced a private placement of up to $800,000 principal amount of 10% senior secured convertible promissory notes due twelve months from the date of issue to certain Company shareholders and other accredited investors. As of December 31, 2006, the Company completed this private placement by selling all notes payable totaling $800,000. The notes are secured by a first priority lien on all of the tangible and intangible personal property of the Company. In May 2007, the due date of these notes was extended to August 2008 and the interest rate increased to 12% per annum during the extension period. In June 2011, the interest rate on all of the notes was reset to 10% and $596,500 of the notes and accrued interest was extended until September 15, 2015. During the fourth quarter of 2012 the remaining $178,749 of unextended notes and the associated accrued interest were extended to September 30, 2015. In June 2013, $225,000 of these notes payable plus accrued interest of $181,125 were converted into 7.4 million shares of the Company’s common stock, which was valued at $1,628,000. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50.
	As of March 31, 2015, the outstanding principal balance on these notes was $114,000. Accrued interest at March 31, 2015 amounted to $115,925. The notes and accrued interest are due on September 15, 2015.
	If an equity financing with total proceeds of more than $5,000,000 occurs while any of these notes are outstanding, holders of notes will have the right, at their option, to convert the outstanding principal and interest of the notes into shares of common stock at a discount of 30% of the price per share in the qualified financing. Since the embedded conversion feature is contingent upon the occurrence of the qualified financing, the value of the contingent conversion feature, if beneficial, will be recognized if the triggering event occurs and the contingency is resolved.

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	NOTE 7 – NOTES PAYABLE
	Notes payable consists of the following at March 31, 2015 and December 31, 2014:
		March 31,		December 31,
		2015		2014
	Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015	$	114,000	$	114,000
	Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)		50,000		50,000
	Notes payable; interest at 8% per annum, principal and accrued interest due at December 1, 2014 (past due)		650,000		650,000
	Notes payable; interest at 5% and 8% per annum, principal and accrued interest due at April 2015		123,000		123,000
	Notes payable; interest at 5% per annum, principal and accrued interest due at June 10, 2015		25,000		—
	Notes payable; interest at 8% per annum, principal and accrued interest due at June 25, 2015		111,102		—
	Less: Debt discount		—		(10,447	)
			1,073,102		926,553
	Less: Current portion		1,073,102		926,553
		$	—	$	—
	The notes payable balance as of March 31, 2015 includes a Series A note payable in the amount of $50,000 with interest of 8% per annum. This note matured in October 2011 and is past due. Accrued interest associated with this note was $21,667 as of March 31, 2015. The notes are in default.
	On June 10, 2014, the Company issued a note payable for $250,000, which included fully vested warrants to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, expiring in five years. The warrants were valued at $39,650 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 248.2%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $34,222 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $34,222 was accreted through interest expense. The note and accrued interest at 8% per annum as was originally due on December 11, 2014, but the Company received approval to extend the maturity until December 31, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $17,741 and the note payable balance was $250,000. As of March 31, 2015, the fair value of the warrant liability was $19,950 and the note payable balance was $250,000. The note is in default.
	On August 5, 2014, the Company issued notes payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $29,725 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $22,914 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $22,914 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $11,178 and the note payable balance was $100,000. As of March 31, 2015, the fair value of the warrant liability was $12,322 and the note payable balance was $100,000. The notes are in default.
	On August 12, 2014, the Company issued a notes payable for $50,000, which included fully vested warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $26,817 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $17,455 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $17,455 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $5,585 and the note payable balance was $50,000. As of March 31, 2015, the fair value of the warrant liability was $5,583 and the note payable balance was $50,000. The note is in default.
	On August 14, 2014, the Company issued a note payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $47,676 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $32,274 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $32,274 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $11,226 and the note payable balance was $100,000. As of March 31, 2015, the fair value of the warrant liability was $11,169 and the note payable balance was $100,000. The note is in default.
	On September 8, 2014, the Company issued notes payable for $150,000, which included fully vested warrants to purchase 900,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $62,544 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $44,140 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $44,140 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $17,385 and the note payable balance was $150,000. As of March 31, 2015, the fair value of the warrant liability was $16,767 and the notes payable balance was $150,000. The notes are in default.
	On December 5, 2014, the Company issued a note payable for $23,000 to a stockholder, which bears interest at 5.0% and is due on April 5, 2015. The note is in default.
	On December 31, 2014, the Company issued a note payable for $100,000, which include fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share expiring in five years. The warrants were valued at $11,812 using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 229.0%, risk free interest rate of 1.68% and expected life of 5 years. The relative fair value of the warrants was $10,563 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition, and is being accreted over the term of the note payable for financial statement purposes. For the three months ended March 31, 2015, $10,447 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on April 1, 2015. This note is currently in default. The warrants are subject to anti-dilution adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is revalued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $11,812 and the note payable balance was $89,553, net of a discount of $10,447. As of March 31, 2015, the fair value of the warrant liability was $11,325 and the note payable balance was $100,000. This note is in default.
	On February 10, 2015, the Company issued a note payable for $25,000, bearing interest at 5.0% to an accredited investor and director of the Company. The note is due on June 10, 2015.
	On March 27, 2015, the Company issued a note payable for $111,102, bearing interest at 8.0% to an accredited investor. The note and accrued interest is due on June 25, 2015. The principal amount of the note and accrued interest is convertible into the next equity financing of the Company. The conversion price under the conversion option will be equal to the price paid by third-party investors in the financing. On March 20, 2014, VerifyMe waived its contractual rights as it relates to this transaction.

Warrant_Liability

Warrant Liability	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Warrant Liability	NOTE 8 – WARRANT LIABILITY
	On December 31, 2012, the Company entered into an Investment Agreement, a Technology and Service Agreement, a Patent and Technology License Agreement and an Asset Purchase Agreement with VerifyMe, and on the same date entered into a Technology and Service Agreement with Zaah Technologies, Inc. (collectively with the VerifyMe agreements, the “Agreements”). Contemplated by those Agreements were warrants issuances by the Company for the purchase of the Company’s common stock.
	The warrants associated with these Agreements are subject to anti-dilution adjustments outlined in the Agreements. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $2.4 million at December 31, 2012. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of March 31, 2015 and December 31, 2014, the fair value of the warrant liability was $865,277 and $787,544.
	On January 1, 2014, the Company issued warrants to purchase 6,349,206 shares of the Company’s common stock as consideration for technology received from VerifyMe under to the Patent and Technology License Agreement dated December 31, 2012. The warrants are exercisable at $0.10 per share. The warrants are subject to anti-dilution adjustments outlined in the Agreement. In accordance with FASB ASC 815, the warrants were classified as a liability with an initial fair value of $444,000, which was immediately expensed as research and development costs. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of March 31, 2015 and December 31, 2014, the fair value of the warrant liability was $116,789 and $121,209.
	The Company made the payment of warrants to VerifyMe on a good faith basis, based on the assumption that the technology conveyed to the Company would be patentable and licensable. The Company has not reached a conclusion that the technology will be patentable and licensable, and can provide no assurance to this effect.
	Should the Company ultimately conclude that the technology received from VerifyMe is patentable and licensable, the Company would be required to make, on January 1, 2015, an additional payment pursuant to Patent and Technology Agreement in the amount of $4,500,000, to be paid by issuing (i) a number of shares of common stock equal to (x) $4,500,000 divided by (y) a price which equals a 10% discount to the market price at the time of issuance and (ii) warrants to purchase an equal number of shares of common stock exercisable at a price of $0.10 per share. Based upon the share price of $0.04 per share, this would result in the issuance of approximately an additional 125 million shares of common stock and warrants to purchase an additional 125 million shares. The $4,500,000 was accrued at December 31, 2014. The number of warrants to be issued based on a stock price of $0.02 at December 31, 2014 was 250 million warrants. The warrants were valued at $4,892,089 as of December 31, 2014, using the Black-Scholes pricing model to calculate the grant-date fair value of the warrants with the following assumptions: no dividend yield, expected volatility of 229.1%, risk free interest rate of 1.65% and expected life of five years. The warrants were valued at $4,615,841 as of March 31, 2015, using the Black-Scholes pricing model to calculate the grant-date fair value of the warrants with the following assumptions: no dividend yield, expected volatility of 190.9%, risk free interest rate of 1.37% and expected life of five years.

Convertible_Preferred_Stock

Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Convertible Preferred Stock	NOTE 9 – CONVERTIBLE PREFERRED STOCK
	Subscription Agreement
	The Company entered into a Subscription Agreement with VerifyMe on January 31, 2013 (the “Subscription Agreement”). Under the terms of the Subscription Agreement, VerifyMe subscribed to purchase 33,333,333 shares of the Company’s Series A preferred stock (the “Preferred Stock”) and a warrant to purchase 33,333,333 shares of the Company’s common stock at an exercise price of $0.12 per share, for $1 million.
	At any time before January 31, 2015, VerifyMe has the right, but not the obligation, to require the Company to repurchase all, but not less than all, of the capital stock of the Company and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefor upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share. This right has not been exercised.
	In accordance with FASB ASC 480 and 815, the Preferred Stock has been classified as permanent equity and was valued at $1 million at January 31, 2013.
	The conversion feature of the Preferred Stock is an embedded derivative, which is classified as a liability in accordance with FASB ASC 815 and was valued in accordance with FASB ASC 470 as a beneficial conversion feature at a fair value of $0 at March 31, 2015 and December 31, 2014. This was classified as an embedded derivative liability and a discount to Preferred Stock. Because the Preferred Stock can be converted at any time, the full amount of the original fair value was accreted and classified as a reduction to the discount on Preferred Stock and a deemed dividend distribution in the full amount of $1 million, in 2013.
	The warrants associated with the Preferred Stock were also classified as a liability since they are subject to anti-dilutive adjustments outlined in the warrant agreement and valued at a fair market value of $2,995,791 at January 31, 2013. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of March 31, 2015 and December 31, 2014, the fair value of the warrants was $526,210 and $494,939, respectively.
	The Preferred Stock has a preference in liquidation that the holders of the Preferred Stock are to be paid out of assets available for distribution prior to holders of common stock. The Preferred Stockholders may cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock can be converted. In addition, the Preferred Stockholders are to be paid dividends, based on the number of shares of Preferred Stock as if the shares had been converted to common shares, prior to the common stockholders receiving a dividend.
	The conversion price of the shares of Preferred Stock is currently $0.03 per share.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 10 – FAIR VALUE OF FINANCIAL INSTRUMENTS
	Derivative Liabilities
	For purposes of determining whether certain instruments are derivatives for accounting treatment, the Company follows the accounting standard that provides guidance for determining whether an equity-linked financial instrument, or embedded feature, is indexed to an entity’s own stock. The standard applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative, and to any freestanding financial instruments that are potentially settled in an entity’s own common stock.
	Liabilities measured at fair value on a recurring basis are summarized as follows:
		Level 1			Level 2		Level 3		Total
	Derivative liability related to fair value of warrants	$	—		$	—	$	6,201,233	$	6,201,233
	Total	$	—		$	—	$	6,201,233	$	6,201,233
	The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs:
	Balance at January 1, 2015	$	6,370,709
	Change in fair value of derivative liabilities		(169,476	)
	Balance at March 31, 2015	$	6,201,233
	As of March 31, 2015, the beneficial conversion feature of the Preferred Stock is treated as an embedded derivative liability and changes in the fair value were recognized in earnings. The Preferred Stock shares are convertible into shares of the Company’s common stock, which did traded in an active securities market, therefore the embedded derivative liability was valued using the following market based inputs:
	Series A Preferred Stock Conversion price	$	0.03
	Intrinsic value of conversion option per share	$	—
	The Company has no assets that are measured at fair value on a recurring basis. There were no assets or liabilities measured at fair value on a non-recurring basis during the three months ended March 31, 2014.
	As of March 31, 2015, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings. These common stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions:
	Annual Dividend Yield	0.00%
	Expected Life (Years)	2.75 - 4.76
	Risk-Free Interest Rate	.89% - 1.37%
	Expected Volatility	177.1% - 193.7%
	Expected volatility was based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company’s expectations of future volatility over the expected term of these warrants. The Company had no reason to believe future volatility over the expected remaining life of these warrants was likely to differ materially from historical volatility. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.

Stock_Options

Stock Options	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options	NOTE 11 – STOCK OPTIONS
	During 1999, the Board of Directors (“Board”) of the Company adopted, with the approval of the stockholders, a Stock Option Plan. In 2000, the Board superseded that plan and created a new Stock Option Plan, pursuant to which it is authorized to grant options to purchase up to 1.5 million shares of common stock. On December 17, 2003, the Board, with approval of the stockholders, superseded the 2000 plan and created the 2003 Stock Option Plan (the “2003 Plan”). Under the 2003 Plan the Company is authorized to grant options to purchase up to 18,000,000 shares of common stock to the Company’s employees, officers, directors, consultants, and other agents and advisors. The Plan is intended to permit stock options granted to employees under the Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the 2003 Plan, which are not intended to qualify as Incentive Stock Options, are deemed to be non-qualified options (“Non-Statutory Stock Options”).
	During 2013, our Board adopted a new omnibus incentive compensation plan (the “2013 Plan”) which will serve as the successor incentive compensation plan to the 2003 Plan, and will provide the Company with an comprehensive plan to design and structure grants of stock options, stock units, stock awards, stock appreciation rights and other stock-based awards for our employees, non-employee directors and certain consultants and advisors. Our Board of Directors believes that the availability of (i) 20,000,000 new shares of our common stock, plus (ii) the 74,004 shares of our common stock available for issuance under the 2003 Plan, will be sufficient to meet the objective.
	As of March 31, 2015, there are 22,725,996 options that have been issued, and 15,274,004 options that are available to be issued under the Plan.
	The 2013 Plan is administered by a committee of the Board (“Stock Option Committee”) which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the plan.
	In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise Incentive Stock Options under all plans of the company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise.
	The Company issued Non-Statutory Stock Options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided.
	Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments.
	Option expense for the three months ended March 31, 2015 was ($54,834).
	The following tables summarize non-employee stock option/warrant activity of the Company since December 31, 2014:
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2014		121,165,874		$	0.01 - $0.20	$	0.1
	Granted		—			—		—
	Exercised		—			—		—
	Expired		—			—		—
	Outstanding, March 31, 2015		121,165,874		$	0.01 to $0.20	$	0.1
	Exercisable, March 31, 2015		121,165,874		$	0.01 to $0.20	$	0.1
	Weighted Average Remaining Life, Exercisable, March 31, 2015 (years)		5.5
	A summary of incentive stock option transactions for employees since December 31, 2014 is as follows:
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2014		53,866,667		$	0.05 - $0.15	$	0.05
	Granted		—			—		—
	Exercised		—			—		—
	Expired/Returned		(1,000,000	)		0.15		—
	Outstanding, March 31, 2015		52,866,667		$	0.05 to $0.15	$	0.05
	Exercisable, March 31, 2015		52,866,667		$	0.05 to $0.15	$	0.06
	Weighted Average Remaining Life, Exercisable, March 31, 2015 (years)		9

Operating_Leases

Operating Leases	3 Months Ended
	Mar. 31, 2015
Leases [Abstract]
Operating Leases	NOTE 12 – OPERATING LEASES
	For the three months ended March 31, 2015 and 2014, total rent expense under leases amounted to $19,369 and $17,727. At March 31, 2015, the Company was obligated under various non-cancelable operating lease arrangements for property as follows:
	2015		56,403
	2016		31,605
		$	88,008
	The Company has advised the landlord that the Company was not going to continue to occupy the space at 3112 M. Street, NW, Washington, DC effective May 1, 2015. Settlement negotiations regarding the lease balance are underway.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 13 – RELATED PARTY TRANSACTIONS
	At March 31, 2015 and 2014, two and five shareholders of the Company held $114,000 and $330,249 of the senior secured convertible notes payable and were owed accrued interest of $115,925 and $328,251.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	NOTE 14 – CONTINGENCIES
	In October 2010, the Company filed suit in the Western District of Pennsylvania against WS Packaging Group, Inc. (“WS”) alleging that WS infringed on one of the Company’s patents in the manufacture of MONOPOLY game pieces on behalf of McDonald’s Corp. On June 4, 2012, both WS and the Company filed a stipulation to dismiss the action without prejudice and enter into settlement negotiations. There are no ongoing negotiations.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 15 – SUBSEQUENT EVENTS
	The Company continues its efforts to raise additional capital. The Company anticipates that current negotiations with a potential investment group may result in a cash infusion in the near term future. There can, however, be no assurance that the Company will be successful in this matter, nor on terms that would be acceptable to the Company.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Nature of the Business	Nature of the Business
	LaserLock Technologies Inc. (the “Company” or “LaserLock”) was incorporated in the State of Nevada on November 10, 1999. The Company is based in Washington, D.C. and its common stock is quoted on the OTC Pink under the ticker symbol “LLTI”. A high-tech solutions company in the field of authenticating people and products, LaserLock offers state-of-the-art solutions to combat identity fraud and counterfeiting utilizing multi-factor authentication and a suite of security pigments for governments, health care providers, the gaming industry, the financial services industry and high-end retailers.
	The Company invests in developing new proprietary color shifting inks that it believes will allow it to penetrate broader markets and result in increased revenues. The Company refines its technologies and their applications, and now has what it believes to be one of the most cost effective and efficient authentication technologies available. Its most recent technology takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in numerous potential new applications ranging from credit cards to drivers licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologies can also be used to protect DVDs, apparel, pharmaceuticals, and virtually any other physical product.
	The Company’s digital solution is a multi-platform (iOS and Android) strong authentication solution that integrates biometrics and geo-location tagging. The solution completely eliminates passwords and the inherently weak security they provide. The solution also removes the user complexity associated with having to manage many complex passwords. The solution can be delivered either as a high availability cloud service, managed by the Company, or as licensed software product for operation on the client’s premises.
	The solution integrates three independent authentication factors – something you have (for instance a smartphone), something you know (for instance a color gesture swipe) and something you are (for instance your facial geometry)—into a simple, fast, intuitive solution. The system can also accurately determine the precise location of the individual using a variety of mechanisms including GPS, cell tower triangulation, IP or Wi-Fi address. Because the solution incorporates biometrics it completely eliminates the possibility that users might share their authentication credentials. The combination of biometrics and geolocation provides extremely strong transactional evidence, making it nearly impossible for an end-user to refute having been part of a transaction.
	The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalize the Company’s current technology.
Basis of Presentation	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on form 10-K for the year ended December 31, 2014, as filed with the SEC. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Comprehensive Income	Comprehensive Income
	The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash, accounts payable and accrued expenses and notes payable. The carrying value of cash, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable and convertible debt approximates its fair value based on rates and other terms currently available to the Company for similar debt instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
Concentration of Credit Risk Involving Cash and Cash Equivalents	Concentration of Credit Risk Involving Cash and Cash Equivalents
	The Company’s cash and cash equivalents are held at two financial institutions. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
Inventory	Inventory
	Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
Property and Equipment	Property and Equipment
	Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operation
Patents and Trademark	Patents and Trademark
	The Company has filed eleven patent applications relating to the company technology. Currently we have 7 U.S. patents, 4 U.S. applications pending for allowance, and 5 foreign applications pending for allowance. The Company has also purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be17 to 20 years.
Long-Lived Assets	Long-Lived Assets
	The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Deferred Financing Costs	Deferred Financing Costs
	Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50 “Debt – Modification and Extinguishments.”
Convertible Notes Payable	Convertible Notes Payable
	Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method which approximates the effective interest method.
Derivative Instruments	Derivative Instruments
	The Company evaluates its convertible debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative, if required to be bifurcated, is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
Revenue Recognition	Revenue Recognition
	In accordance with SEC Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
Income Taxes	Income Taxes
	The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
Stock-based Payments	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
	All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid-in capital in stockholders’ equity over the applicable service periods.
Advertising Costs	Advertising Costs
	Advertising costs are expensed as incurred. Advertising costs were approximately $158 and $27,283 for the three months ended March 31, 2015 and 2014 and are included in sales and marketing expenses.
Research and Development Costs	Research and Development Costs
	In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the three months ended March 31, 2015 and 2014 were $120,386 and $864,729.
Basic and Diluted Net Income per Share of Common Stock	Basic and Diluted Net Income per Share of Common Stock
	The Company follows FASB ASC 260 when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Since the Company reported a net loss for the three months ended March 31, 2015 and 2014, common stock equivalents, including convertible preferred stock, convertible debt, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share during the years were the same.
Segment Information	Segment Information
	The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by ASC 280 can be found in the financial statements.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements
	As of March 31, 2015 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted
	As of March 31, 2015, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company’s financial statements through 2016.
Reclassifications	Reclassifications
	Certain amounts in 2014 statement of operations have been reclassified in order for them to conform with the 2015 presentation.

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Equipment	Equipment consists of the following:
		March 31,		December 31,
		2015		2014
	Furniture and Fixtures	$	219,871	$	219,871
	Equipment		16,155		16,155
			236,026		236,026
	Less: Accumulated depreciation		178,518		161,205
		$	57,508	$	74,821

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at March 31, 2015 and December 31, 2014:
		March 31,		December 31,
		2015		2014
	Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015	$	114,000	$	114,000
	Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)		50,000		50,000
	Notes payable; interest at 8% per annum, principal and accrued interest due at December 1, 2014 (past due)		650,000		650,000
	Notes payable; interest at 5% and 8% per annum, principal and accrued interest due at April 2015		123,000		123,000
	Notes payable; interest at 5% per annum, principal and accrued interest due at June 10, 2015		25,000		—
	Notes payable; interest at 8% per annum, principal and accrued interest due at June 25, 2015		111,102		—
	Less: Debt discount		—		(10,447	)
			1,073,102		926,553
	Less: Current portion		1,073,102		926,553
		$	—	$	—

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Liabilities Measured at Fair Value on a Recurring Basis	Liabilities measured at fair value on a recurring basis are summarized as follows:
		Level 1			Level 2		Level 3		Total
	Derivative liability related to fair value of warrants	$	—		$	—	$	6,201,233	$	6,201,233
	Total	$	—		$	—	$	6,201,233	$	6,201,233
Fair Value Measurements within Fair Value Hierarchy of Derivative Liabilities Using Level 3 Inputs	The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs:
	Balance at January 1, 2015	$	6,370,709
	Change in fair value of derivative liabilities		(169,476	)
	Balance at March 31, 2015	$	6,201,233
Embedded Derivative Liability Valuation Assumptions	The Preferred Stock shares are convertible into shares of the Company’s common stock, which did traded in an active securities market, therefore the embedded derivative liability was valued using the following market based inputs:
	Series A Preferred Stock Conversion price	$	0.03
	Intrinsic value of conversion option per share	$	—
Schedule of Common Stock Purchase Warrants Valuation Assumptions	As of March 31, 2015, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings. These common stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions:
	Annual Dividend Yield	0.00%
	Expected Life (Years)	2.75 - 4.76
	Risk-Free Interest Rate	.89% - 1.37%
	Expected Volatility	177.1% - 193.7%

Stock_Options_Tables

Stock Options (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Non-employee Stock Option/Warrant Activity	The following tables summarize non-employee stock option/warrant activity of the Company since December 31, 2014:
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2014		121,165,874		$	0.01 - $0.20	$	0.1
	Granted		—			—		—
	Exercised		—			—		—
	Expired		—			—		—
	Outstanding, March 31, 2015		121,165,874		$	0.01 to $0.20	$	0.1
	Exercisable, March 31, 2015		121,165,874		$	0.01 to $0.20	$	0.1
	Weighted Average Remaining Life, Exercisable, March 31, 2015 (years)		5.5
Schedule of Incentive Stock Option Transactions for Employees	A summary of incentive stock option transactions for employees since December 31, 2014 is as follows:
		Option/Warrant			Exercise		Weighted Average
		Shares			Price		Exercise
							Price
	Outstanding, December 31, 2014		53,866,667		$	0.05 - $0.15	$	0.05
	Granted		—			—		—
	Exercised		—			—		—
	Expired/Returned		(1,000,000	)		0.15		—
	Outstanding, March 31, 2015		52,866,667		$	0.05 to $0.15	$	0.05
	Exercisable, March 31, 2015		52,866,667		$	0.05 to $0.15	$	0.06
	Weighted Average Remaining Life, Exercisable, March 31, 2015 (years)		9

Operating_Leases_Tables

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2015
Leases [Abstract]
Schedule of Non-cancelable Operating Lease Arrangements for Property	At March 31, 2015, the Company was obligated under various non-cancelable operating lease arrangements for property as follows:
	2015		56,403
	2016		31,605
		$	88,008

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	Segment
	Institution
Schedule Of Significant Accounting Policies [Line Items]
Number of financial institutions at which company's cash and cash equivalents are held	2
Depreciation method of property and equipment	Straight-line method
Research and development costs	$120,386	$864,729
Number of operating segment	1
Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents filed	11
Number of patents issued	7
Amortization method of patents	Straight-line basis
Patents and Trademark | UNITED STATES
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents pending for allowance.	4
Patents and Trademark | Foreign Countries
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents pending for allowance.	5
Sales and marketing expenses
Schedule Of Significant Accounting Policies [Line Items]
Advertising costs	$158	$27,283
Minimum
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	5 years
Minimum | Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Estimated lives of patents	17 years
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	7 years
Maximum | Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Estimated lives of patents	20 years

Property_and_Equipment_Equipme

Property and Equipment - Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment, Net [Abstract]
Furniture and Fixtures	$219,871	$219,871
Equipment	16,155	16,155
Property, Plant and Equipment, Gross, Total	236,026	236,026
Less: Accumulated depreciation	178,518	161,205
Capital equipment, net of accumulated depreciation of $178,518 and $161,205 as of March 31, 2015 and 2014	$57,508	$74,821

Plant_and_Equipment_Additional

Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment, Net [Abstract]
Depreciation of property and equipment	$17,313	$17,313

Patents_and_Trademark_Addition

Patents and Trademark - Additional Information (Detail) (Patents and Trademark, USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	Patents
Finite-Lived Intangible Assets [Line Items]
Number of patents issued	7
Number of provisional patents filed	11
Amortization method of patents	Straight-line basis
Capitalized patent costs	$0	$21,954
Amortization expense	$4,114	$3,277
Anti Counterfeiting Technology
Finite-Lived Intangible Assets [Line Items]
Number of patents issued	7
Number of provisional patents filed	4
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of patents	17 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of patents	20 years

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$0	$0
Unrecognized tax benefits			0
Interest or penalties related to unrecognized tax benefits			0
Change in unrecognized tax benefits	0
Accrual for uncertain tax positions	$0

Senior_Secured_Convertible_Not1

Senior Secured Convertible Notes Payable -Related Parties - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
Share data in Millions, unless otherwise specified	Jun. 30, 2013	Mar. 31, 2015	Dec. 31, 2012	Dec. 31, 2006	Jun. 30, 2011	31-May-07	Feb. 28, 2006
Debt Instrument [Line Items]
Accrued interest		115,925
Outstanding principal balance on notes		114,000
Senior Secured Convertible Promissory Notes
Debt Instrument [Line Items]
Debt instrument principal amount	225,000				596,500		800,000
Interest rate					10.00%	12.00%	10.00%
Sale price of notes payable				800,000
Remaining debt and accrued interest was extended until September 15, 2015			178,749
Accrued interest	181,125
Common stock shares issued on conversion of debt (in shares)	7.4
Amount of notes converted into common stock shares	$1,628,000
Debt instrument conditional covenants amount		If an equity financing with total proceeds of more than $5,000,000 occurs while any of these notes are outstanding, holders of notes will have the right, at their option, to convert the outstanding principal and interest of the notes into shares of common stock at a discount of 30% of the price per share in the qualified financing.
Percentage of discount on price per share		30.00%

Notes_Payable_Schedule_of_Note

Notes Payable - Schedule of Notes Payable (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Less: Debt discount		($10,447)
Notes payable	1,073,102	926,553
Notes payable	1,073,102	926,553
Less: Current portion	959,102	812,553
Long-term portion	0	0
Adjustment
Debt Instrument [Line Items]
Less: Current portion	1,073,102	926,553
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015
Debt Instrument [Line Items]
Notes payable	114,000	114,000
Notes payable	114,000	114,000
Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)
Debt Instrument [Line Items]
Notes payable	50,000	50,000
Notes payable	50,000	50,000
Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)
Debt Instrument [Line Items]
Notes payable	650,000	650,000
Notes payable	650,000	650,000
Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015
Debt Instrument [Line Items]
Notes payable	123,000	123,000
Notes payable	123,000	123,000
Notes payable; interest at 5% per annum, principal and accrued interest due at June 10, 2015
Debt Instrument [Line Items]
Notes payable	25,000
Notes payable	25,000
Notes payable; interest at 8% per annum, principal and accrued interest due at June 25, 2015
Debt Instrument [Line Items]
Notes payable	111,102
Notes payable	$111,102

Notes_Payable_Schedule_of_Note1

Notes Payable - Schedule of Notes Payable (Parenthetical) (Detail)	Mar. 31, 2015	Dec. 31, 2014
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015
Debt Instrument [Line Items]
Interest rate	10.00%	10.00%
Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)
Debt Instrument [Line Items]
Interest rate	8.00%	8.00%
Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)
Debt Instrument [Line Items]
Interest rate	8.00%	8.00%
Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015
Debt Instrument [Line Items]
Interest rate	5.00%	8.00%
Notes payable; interest at 5% per annum, principal and accrued interest due at June 10, 2015
Debt Instrument [Line Items]
Interest rate	5.00%
Notes payable; interest at 8% per annum, principal and accrued interest due at June 25, 2015
Debt Instrument [Line Items]
Interest rate	8.00%

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jun. 10, 2014	Aug. 05, 2014	Aug. 12, 2014	Aug. 14, 2014	Sep. 08, 2014	Mar. 27, 2015	Feb. 10, 2015	Dec. 05, 2014
Debt Instrument [Line Items]
Note payable balance	$959,102		$812,553
Proceeds from issuance of notes payable	136,102
Accumulated discount, notes payable (in dollars)			10,447
Interest expense	30,250	10,907
Warrant | June 10, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	19,950		17,741
Warrant | August 5, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	12,322		11,178
Warrant | August 12, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	5,583		5,585
Warrant | August 14, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	11,169		11,226
Warrant | September 8, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	16,767		17,385
Warrant | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Fair value of warrant liability	11,325		11,812
Series A Notes Payable
Debt Instrument [Line Items]
Note payable balance	50,000
Interest rate, notes payable	8.00%
Accrued interest	21,667
Notes Payable | June 10, 2014
Debt Instrument [Line Items]
Note payable balance	250,000		250,000
Interest rate, notes payable			8.00%
Interest expense			34,222
Notes Payable | August 5, 2014
Debt Instrument [Line Items]
Note payable balance	100,000		100,000
Interest rate, notes payable			8.00%
Interest expense			22,914
Notes Payable | August 12, 2014
Debt Instrument [Line Items]
Note payable balance	50,000		50,000
Interest rate, notes payable			8.00%
Interest expense			17,455
Notes Payable | August 14, 2014
Debt Instrument [Line Items]
Note payable balance	100,000		100,000
Interest rate, notes payable			8.00%
Interest expense			32,274
Notes Payable | September 8, 2014
Debt Instrument [Line Items]
Note payable balance	150,000		150,000
Interest rate, notes payable			8.00%
Interest expense			44,140
Notes Payable | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Note payable balance	100,000		89,553
Interest rate, notes payable	8.00%
Interest expense	10,447
Notes Payable | Warrant | June 10, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable				250,000
Number of common stock called by warrants (in shares)				1,000,000
Exercise price (in dollars per share)				$0.10
Fair value of warrant liability				39,650
Expected volatility				248.20%
Risk-Free Interest Rate				1.67%
Expected warrant term				5 years
Accumulated discount, notes payable (in dollars)				34,222
Notes Payable | Warrant | August 5, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable					100,000
Number of common stock called by warrants (in shares)					600,000
Exercise price (in dollars per share)					$0.05
Fair value of warrant liability					29,725
Expected volatility					233.80%
Risk-Free Interest Rate					1.67%
Expected warrant term					5 years
Accumulated discount, notes payable (in dollars)					22,914
Notes Payable | Warrant | August 12, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable						50,000
Number of common stock called by warrants (in shares)						300,000
Exercise price (in dollars per share)						$0.05
Fair value of warrant liability						26,817
Expected volatility						233.80%
Risk-Free Interest Rate						1.67%
Expected warrant term						5 years
Accumulated discount, notes payable (in dollars)						17,455
Notes Payable | Warrant | August 14, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable							100,000
Number of common stock called by warrants (in shares)							600,000
Exercise price (in dollars per share)							$0.05
Fair value of warrant liability							47,676
Expected volatility							233.80%
Risk-Free Interest Rate							1.67%
Expected warrant term							5 years
Accumulated discount, notes payable (in dollars)							32,274
Notes Payable | Warrant | September 8, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable								150,000
Number of common stock called by warrants (in shares)								900,000
Exercise price (in dollars per share)								$0.05
Fair value of warrant liability								62,544
Expected volatility								233.80%
Risk-Free Interest Rate								1.67%
Expected warrant term								5 years
Accumulated discount, notes payable (in dollars)								44,140
Notes Payable | Warrant | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable			100,000
Number of common stock called by warrants (in shares)			600,000
Exercise price (in dollars per share)			$0.05
Fair value of warrant liability			11,812
Expected volatility			229.00%
Risk-Free Interest Rate			1.68%
Expected warrant term			5 years
Accumulated discount, notes payable (in dollars)			10,447
Notes Payable | Warrant | Debt Instrument Date December 2014 | During the issuance
Debt Instrument [Line Items]
Accumulated discount, notes payable (in dollars)			10,563
Notes Payable | Director
Debt Instrument [Line Items]
Interest rate, notes payable									8.00%	5.00%
Proceeds from issuance of notes payable									111,102	25,000
Note due date									25-Jun-15	10-Jun-15
Notes Payable | Stockholder
Debt Instrument [Line Items]
Interest rate, notes payable											5.00%
Proceeds from issuance of notes payable											$23,000
Note due date											5-Apr-15

Warrant_Liability_Additional_I

Warrant Liability - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended	12 Months Ended
	Jan. 01, 2014	Jan. 01, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2012
Major Agreements [Line Items]
Warrant liability			$6,201,233	$6,370,709
Verify Me | Warrants issued on January 1, 2014
Major Agreements [Line Items]
Fair value of warrant liability			116,789	121,209
Number of warrants issued	6,349,206
Exercise price (in dollars per share)	$0.10
Agreements | Zaah Technologies
Major Agreements [Line Items]
Warrant liability					2,400,000
Fair value of warrant liability			865,277	787,544
Agreements | Verify Me | Research and Development Expense
Major Agreements [Line Items]
Initial fair value of warrant expensed as research and development cost	444,000
Patent And Technology Agreement
Major Agreements [Line Items]
Exercise price (in dollars per share)		$0.10
Additional payment for patent and technology		4,500,000
Discount to market price at time of issuance		10.00%
Current share price (in dollars per share)		$0.04
Additional shares issued for patent and technology agreement (in shares)		125,000,000
Number of common stock shares purchased under warrants (in shares)		125,000,000
Patent And Technology Agreement | Stock Options And Warrants
Major Agreements [Line Items]
Number of warrants to be issued(in shares)				250,000,000
Exercise price of warrant to be issued(in dollars per share)				$0.02
Warrant to be issued value			$4,615,841	$4,892,089
Patent And Technology Agreement | Stock Options And Warrants | Warrant
Major Agreements [Line Items]
Dividend yield			0.00%	0.00%
Expected volatility			190.90%	229.10%
Risk free interest			1.37%	1.65%
Expected warrant term			5 years	5 years

Convertible_Preferred_Stock_Ad

Convertible Preferred Stock - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Jan. 31, 2013	Jan. 31, 2013
Class of Stock [Line Items]
Preferred stock value	$633,333	$633,333
Fair value of warrants	526,210	494,939
Convertible Preferred Stock Subject to Mandatory Redemption [Member]
Class of Stock [Line Items]
Preferred stock value			1,000,000	1,000,000
Subscription Agreement
Class of Stock [Line Items]
Convertible preferred stock description	At any time before January 31, 2015, VerifyMe has the right, but not the obligation, to require the Company to repurchase all, but not less than all, of the capital stock of the Company and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefor upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share.
Excess amount for incurring indebtedness	2,000,000
Exercise price of capital stock or warrant	$0.03
Fair value of warrants			2,995,791
Subscription Agreement | Verify Me
Class of Stock [Line Items]
Beneficial conversion feature at fair market value	0	0
Deemed dividend distribution				1,000,000
Subscription Agreement | Convertible Preferred Stock | Verify Me
Class of Stock [Line Items]
Number of preferred stock purchased			33,333,333
Subscription Agreement | Common Stock | Verify Me
Class of Stock [Line Items]
Number of common stock called by warrants (in shares)			33,333,333	33,333,333
Value of shares issued			$1,000,000
Exercise price of warrants			$0.12	$0.12
Subscription Agreement | Preferred Class
Class of Stock [Line Items]
Initial conversion price per share (in dollars per share)	$0.03

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Detail) (Fair Value on a Recurring Basis, USD $)	Mar. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of warrants	$6,201,233
Total	6,201,233
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of warrants	6,201,233
Total	$6,201,233

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Fair Value Measurements within Fair Value Hierarchy of Derivative Liabilities Using Level 3 Inputs (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$6,370,709
Change in fair value of derivative liabilities	-169,476
Ending balance	$6,201,233

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Embedded Derivative Liability Valuation Assumptions (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Series A Preferred Stock Conversion price	$0.03
Intrinsic value of conversion option per share	$0

Fair_Value_of_Financial_Instru5

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]
Assets measured at fair value on recurring basis	$0
Assets or liabilities measured at fair value on non-recurring basis	$0

Fair_Value_of_Financial_Instru6

Fair Value of Financial Instruments - Schedule of Common Stock Purchase Warrants Valuation Assumptions (Detail) (Warrant)	3 Months Ended
	Mar. 31, 2015
Fair Value, Option, Quantitative Disclosures [Line Items]
Annual Dividend Yield	0.00%
Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected Life (Years)	2 years 9 months
Risk-Free Interest Rate	0.89%
Expected volatility	177.10%
Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected Life (Years)	4 years 9 months 4 days
Risk-Free Interest Rate	1.37%
Expected volatility	193.70%

Stock_Options_Additional_infor

Stock Options - Additional information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2013	Dec. 17, 2003	Dec. 31, 2000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option expense	($54,834)
Stock Option 2003 Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options		20,000,000
Number of options available to be issued		74,004
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, description	The exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise Incentive Stock Options under all plans of the company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise.
Stock Options | Stock Option 2003 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options			18,000,000
Number of options available to be issued	15,274,004
Number of option issued	22,725,996
Stock Options | Stock Option 2000 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options				1,500,000

Stock_Options_NonEmployee_Stoc

Stock Options - Non-Employee Stock Option/Warrant Activity (Detail) (Stock Options And Warrants, USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Option/Warrant Shares
Outstanding, beginning balance	121,165,874
Granted	0
Exercised	0
Expired	0
Outstanding, ending balance	121,165,874
Exercisable, March 31, 2015	121,165,874
Weighted Average Remaining Life, Exercisable, March 31, 2015 (years)	5 years 6 months
Exercise Price
Granted	$0
Exercised	$0
Expired	$0
Weighted Average Exercise Price
Outstanding, beginning balance	$0.10
Granted	$0
Exercised	$0
Expired	$0
Outstanding, ending balance	$0.10
Exercisable, March 31, 2015	$0.10
Minimum
Exercise Price
Outstanding, beginning balance		$0.01
Outstanding, ending balance	$0.01	$0.01
Exercisable, March 31, 2015	$0.01
Maximum
Exercise Price
Outstanding, beginning balance		$0.20
Outstanding, ending balance	$0.20	$0.20
Exercisable, March 31, 2015	$0.20

Stock_Options_Incentive_Stock_

Stock Options - Incentive Stock Option Transactions (Detail) (Incentive Stock Options [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Option/Warrant Shares
Outstanding, beginning balance	53,866,667
Granted	0
Exercised	0
Expired/Returned	-1,000,000
Outstanding, ending balance	52,866,667
Exercisable, March 31, 2015	52,866,667
Weighted Average Remaining Life, Exercisable, March 31, 2015 (years)	9 years
Exercise Price
Granted	$0
Exercised	$0
Expired/Returned	$0.15
Weighted Average Exercise Price
Outstanding, beginning balance	$0.05
Granted	$0
Exercised	$0
Expired/Returned	$0
Outstanding, ending balance	$0.05
Exercisable, March 31, 2015	$0.06
Minimum
Exercise Price
Outstanding, beginning balance		$0.05
Outstanding, ending balance	$0.05	$0.05
Exercisable, March 31, 2015	$0.05
Maximum
Exercise Price
Outstanding, beginning balance		$0.15
Outstanding, ending balance	$0.15	$0.15
Exercisable, March 31, 2015	$0.15

Operating_Leases_Additional_In

Operating Leases - Additional Information (Detail) (General and Administrative Expense, USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
General and Administrative Expense
Operating Leased Assets [Line Items]
Total rent expense under leases	$19,369	$17,727

Operating_Leases_Schedule_of_N

Operating Leases - Schedule of Non-cancelable Operating Lease Arrangements for Property (Detail) (USD $)	Mar. 31, 2015
Leases, Operating [Abstract]
2015	$56,403
2016	31,605
Total	$88,008

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
			Shareholder
Related Party Transaction [Line Items]
Convertible notes payable	$114,000	$114,000
Senior Secured Convertible Promissory Notes
Related Party Transaction [Line Items]
Number of shareholders			5
Convertible notes payable			330,249
Amount of accrued interest owed by shareholders			328,251
Senior Secured Convertible Promissory Notes | 2 Shareholders
Related Party Transaction [Line Items]
Number of shareholders	2
Convertible notes payable	114,000
Amount of accrued interest owed by shareholders	$115,925